Walleye Capital LLC Apellis Pharmaceuticals, Inc. Transaction History
Walleye Capital LLC
- $46.2 Billion
- Q3 2024
A detailed history of Walleye Capital LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 200 shares of APLS stock, worth $5,702. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 12,800
98.44%
Holding current value
$5,702
Previous $491,000
98.98%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding APLS
# of Institutions
304Shares Held
109MCall Options Held
3.87MPut Options Held
1.12M-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$339 Million14.88% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$336 Million0.07% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$317 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$286 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$165 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.13B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...